SCHEMBL25199979

SCHEMBL25199979

CN1CCN(CC(=O)N(O)Cc2ccc(Nc3ccc(-c4ccccc4)cc3)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ CHKA P35790 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ KMT2A Q03164 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ MGLL Q99685 1/20 0.42
▸ ACHE P22303 1/20 0.41
▸ LTB4R2 Q9NPC1 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ FAAH O00519 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25190439 0.90 ALDH1A1 (0.42) CHKAALDH1A1KMT2AKDM4ETSHR
SCHEMBL25194243 0.89 IKBKE (0.47) LMNASMN1; SMN2RAB9ANPC1HDAC1
SCHEMBL25190447 0.88 RORC (0.41) LMNASMN1; SMN2RAB9ACHKAGAA
SCHEMBL25198063 0.88 LMNA (0.60) LMNASMN1; SMN2RAB9AGAAALDH1A1
SCHEMBL25190292 0.84 KMT2A (0.57) LMNASMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL25188470 0.84 RORC (0.42) LMNASMN1; SMN2RAB9ANPC1GAA
SCHEMBL26154420 0.84 HRH3 (0.47) RAB9ANPC1CHKAALDH1A1ACHE
SCHEMBL25190319 0.84 ATM (0.38) LMNASMN1; SMN2RAB9AGAAALDH1A1
SCHEMBL25190133 0.83 CHKA (0.45) RAB9ANPC1CHKAGAAALDH1A1
SCHEMBL25188122 0.83 MAPT (0.43) SMN1; SMN2RAB9ANPC1CHKAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 — — CN disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
CN-115151252-A Iron death inhibitors diarylamine para-acetamides 维泰瑞隆有限公司 2022-10-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES AIFM2, FECH, GPX4 LMNA 3613/4885SMN1; SMN2 724/4885RAB9A 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback